3 days Ago By ABMN Staff
Investment analysts at StockNews.com started coverage on shares of Vanda Pharmaceuticals ( NASDAQ:VNDA – Get Free Report ) in a research note issued on Saturday. The firm set a “hold” rating on the biopharmaceutical company’s stock.
Separately, Cantor Fitzgerald increased their price objective on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a report on Thursday, August 1st.
Read Our Latest Analysis on VNDA Vanda Pharmaceuticals Stock Performance Vanda Pharmaceuticals ( NASDAQ:VNDA – Get Free Report ) last posted its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter.
Vanda Pharmaceuticals had a negative return on equity of 2.01% and a negative net margin of 6.00%.
The company had revenue of $50.47 million during the quarter. As a group, equities research analysts forecast that Vanda Pharmaceuticals will post -0.
49 EPS for the current fiscal year. Institutional Trading of Vanda Pharmaceuticals A number of large investors have recently made changes to their positions in the stock. Aristides Capital LLC bought a new position in shares of Vanda Pharmaceuticals during the fourth quarter valued at approximately $272,000.
GSA Capital Partners LLP increased its stake in Vanda Pharmaceuticals by 39.8% during the 4th quarter. GSA Capital Partners LLP now owns 567,756 shares of the biopharmaceutical company’s stock valued at $2,396,000 after purchasing an additional 161,737 shares in the last quarter.
Los Angeles Capital Management LLC lifted its stake in shares of Vanda Pharmaceuticals by 17.6% during the first quarter. Los Angeles Capital Management LLC now owns 431,224 shares of the biopharmaceutical company’s stock worth $1,772,000 after buying an additional 64,670 shares during the period.
China Universal Asset Management Co. Ltd. increased its position in shares of Vanda Pharmaceuticals by 65.
9% in the 1st quarter. China Universal Asset Management Co. Ltd.
now owns 11,045 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 4,387 shares during the period. Finally, BNP Paribas Financial Markets increased its holdings in shares of Vanda Pharmaceuticals by 70.1% in the first quarter.
BNP Paribas Financial Markets now owns 101,363 shares of the biopharmaceutical company’s stock valued at $417,000 after purchasing an additional 41,767 shares during the period. 88.14% of the stock is owned by hedge funds and other institutional investors.
Vanda Pharmaceuticals Company Profile ( Get Free Report ) Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Recommended Stories Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
